Evidence map›Paper›PMID 23226274›Full record

ArticlePloS one2012

CD81 interacts with the T cell receptor to suppress signaling.

Safak Isil Cevik, Nazli Keskin, Serkan Belkaya, Meral Ilcim Ozlu, Emre Deniz, Uygar Halis Tazebay, Batu Erman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Safak Isil CevikBiological Sciences and Bioengineering Program, Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Turkey.
Nazli Keskin
Serkan Belkaya
Meral Ilcim Ozlu
Emre Deniz
Uygar Halis Tazebay
Batu Erman
Sabancı Üniversitesi · TRBilkent University · TR

Funding

Role of CD3delta in T-lymphocyte functionR01TW007270 · FIC · SABANCI UNIVERSITY · PI ERMAN, BATU · 2007 to 2011
$253k
FIC NIH HHS 5R01TW007270FIC NIH HHS R01 TW007270
6 · The paper itself

Abstract

CD81 (TAPA-1) is a ubiquitously expressed tetraspanin protein identified as a component of the B lymphocyte receptor (BCR) and as a receptor for the Hepatitis C Virus. In an effort to identify trans-membrane proteins that interact with the T-cell antigen receptor (TCR), we performed a membrane yeast two hybrid screen and identified CD81 as an interactor of the CD3delta subunit of the TCR. We found that in the absence of CD81, in thymocytes from knockout mice, TCR engagement resulted in stronger signals. These results were recapitulated in T cell lines that express low levels of CD81 through shRNA mediated silencing. Increased signaling did not result from alterations in the levels of TCR on the surface of T lymphocytes. Although CD81 is not essential for normal T lymphocyte development, it plays an important role in regulating TCR and possibly pre-TCR signal transduction by controlling the strength of signaling. CD81 dependent alterations in thymocyte signaling are evident in increased CD5 expression on CD81 deficient double positive (DP) thymocytes. We conclude that CD81 interacts with the T cell receptor to suppress signaling.

Indexed as

AnimalsCD5 AntigensCell CommunicationGene ExpressionHEK293 CellsHumansLymphocyte ActivationMiceMice, KnockoutPlasmidsProtein BindingReceptors, Antigen, T-Cell, gamma-deltaRNA, Small InterferingSignal TransductionTetraspanin 28ThymocytesCD5 AntigensReceptors, Antigen, T-Cell, gamma-deltaRNA, Small InterferingTetraspanin 28

Identifiers

PMID23226274
PMCPMC3511562
OpenAlexW2069359540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.